Reviewing Solventum (NYSE:SOLV) & Delcath Systems (NASDAQ:DCTH)

Solventum (NYSE:SOLV) and Delcath Systems (NASDAQ:DCTH) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Institutional & Insider Ownership

61.1% of Delcath Systems shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Solventum and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solventum	17.26%	25.09%	8.78%
Delcath Systems	0.56%	0.46%	0.42%

Risk and Volatility

Solventum has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Valuation and Earnings

This table compares Solventum and Delcath Systems”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.32 billion	1.81	$1.56 billion	$8.18	10.85
Delcath Systems	$85.23 million	6.56	$2.70 million	$0.01	1,611.00

Solventum has higher revenue and earnings than Delcath Systems. Solventum is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Solventum and Delcath Systems, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1	3	8	0	2.58
Delcath Systems	1	0	5	1	2.86

Solventum currently has a consensus price target of $92.80, suggesting a potential upside of 4.55%. Delcath Systems has a consensus price target of $23.17, suggesting a potential upside of 43.80%. Given Delcath Systems’ stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than Solventum.

Summary

Solventum beats Delcath Systems on 8 of the 15 factors compared between the two stocks.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.